Takeda Pharmaceutical Company Limited has inaugurated its new office in Biopolis, Singapore. The expanded space will host key Takeda functions: its Emerging Markets Business Unit headquarters, Takeda Development Center Asia, and Vaccine Business Unit. The new office will house the Takeda Emerging Markets Business Unit, including Asia-Pacific, as well as the Takeda Vaccine Business Unit and the regional Research and Development Center.

Takeda's decision to relocate the central hub of its Emerging Markets Business Unit said that it shows the momentum of the Emerging Markets business and the importance of the Asia-Pacific region as a pillar of Takeda's long-term growth strategy. The Vaccine Business Unit based in Singapore hosts a laboratory for analytics and development of vaccines to protect against infectious diseases in the region. One vaccine targets dengue fever and will soon enter Phase III clinical trials. Takeda's Development function is responsible for clinical studies across 12 countries in Asia, supporting clinical activities for compounds in Takeda's key therapeutic areas.

Source: Takeda